Semaglutide Clinics Dallas-Fort Worth: Verified GLP-1 Weight Loss Providers 2026

DFW Semaglutide Market Overview

The Dallas-Fort Worth metroplex is one of the most active semaglutide markets in the United States. With a population of approximately 8 million across 12 counties and an obesity rate of 33.2% among adults, the demand for GLP-1 weight-loss therapies has produced a dense provider landscape stretching from Dallas’ Knox-Henderson neighborhood to Frisco’s Legacy West corridor and south to Fort Worth’s Alliance area [1][2].

SemaVerified has independently verified 40 semaglutide clinics across 14 DFW cities as of March 2026, through a combination of direct clinic outreach, website review, and published pricing verification. These clinics include internal medicine practices, med spas, direct primary care membership models, bariatric surgery centers, plastic surgery practices, and national franchise locations. Each has been verified for licensure, active prescribing, and current semaglutide availability [1].

The DFW market reflects several defining characteristics. Cash prices average $311 per month for compounded semaglutide, which is 4% below the national average of $325 reported by major telehealth platforms in late 2025 [3]. However, only 8 of the 40 clinics publish fully transparent all-in pricing that includes consultation fees, lab work, and ongoing medication costs. The remaining 32 clinics require a consultation before disclosing the complete cost structure — a pattern that disadvantages patients who are comparing options [1].

The GLP-1 market nationally has grown at a pace that few healthcare sectors have matched. Semaglutide (Wegovy) prescriptions exceeded 4 million in the United States by late 2025, up from under 500,000 in 2022 — an eightfold increase in three years [4]. In Texas, GLP-1 prescriptions grew 42% year-over-year in 2025, with DFW accounting for an estimated 28% of statewide prescription volume based on pharmacy claims data [5]. This growth has driven new clinic openings: DFW added approximately 11 new semaglutide providers in 2025 alone, most of them in the Frisco-Plano-Allen growth corridor [1].

Pricing in DFW has remained relatively stable despite market expansion. The arrival of multiple compounding pharmacies serving the Texas market — including Empower Pharmacy in Houston — has created downward pressure on medication costs, with the lowest sustained cash prices in Dallas holding at $249/month. Upward pressure comes from premium positioning by newer clinics in affluent markets like Frisco ($328/month average) and Southlake ($325/month excluding promotional pricing), where patients appear less price-sensitive and providers compete on monitoring quality and service breadth rather than price [1][2].

Branded Wegovy lists at $1,349 per month before insurance, a price that places it out of reach for most uninsured DFW patients. Novo Nordisk’s savings card reduces the copay to $0 for commercially insured patients with eligible plans, but the majority of DFW weight-loss clinic patients are cash-pay, making compounded semaglutide the practical default for the metro [6]. The regulatory status of compounded semaglutide remains a key market dynamic: the FDA shortage designation that permits compounding may be resolved in 2026, which would require clinics and patients to transition to branded products or pursue alternative GLP-1 therapies like tirzepatide [7].

DFW Semaglutide Topic Guides

Use the guides below to find the specific information you need. Each guide covers one topic in depth using verified DFW-specific data from 40 clinics. None of these pages contain paid placements.

Find Semaglutide Clinics By City

The 40 verified DFW clinics are spread across 7 cities with direct clinic presence. Residents in the 7 surrounding cities are served by providers within a 10–20 minute drive. Click any city for a full list of verified clinics, pricing, and provider details.

Farmers Branch, which has 2 verified clinics (Vitality DPC and Simply Direct Medicine), is included in our dataset but does not have a dedicated city page due to its smaller provider footprint. Both clinics are listed in our full clinic comparison.

DFW Semaglutide Market Summary

Sources: SemaVerified clinic database [1], U.S. Census Bureau [2], Hims & Hers Health Q4 2025 earnings [3]. Data as of March 21, 2026.

What Makes DFW Different From Other Major Metros

The Dallas-Fort Worth semaglutide market has several characteristics that distinguish it from other large U.S. metros. First, the compounding pharmacy ecosystem is unusually well-developed due to Texas’s size and its proximity to Empower Pharmacy in Houston, one of the largest FDA-registered 503B compounding facilities in the United States. This gives DFW clinics access to a higher-volume, lower-cost supply chain than metros that rely on smaller regional compounders, keeping the average cash price below the national average despite the metro’s general premium positioning in healthcare services [1][5].

Second, DFW’s corporate employer base — which includes headquarters for Toyota, AT&T, JPMorgan Chase, Capital One, Exxon, and American Airlines — creates a concentrated population of commercially insured patients with employer-sponsored plans that often cover Wegovy. The Plano-Frisco-Allen corridor, where many of these corporate headquarters are located, has the highest density of clinics in the metro outside of Dallas proper. Patients in this corridor have the highest probability of both insurance coverage and proximity to multiple providers, giving them meaningful choice [1][2].

Third, the DFW telehealth infrastructure is more developed than most comparable metros. Several DFW-based clinics offer fully virtual care pathways — consultation, prescription, and medication delivery without an in-person visit — which has expanded access in the seven cities in our coverage area that have no local clinic. InjectCo in Dallas, for example, explicitly advertises service to Southlake and Fort Worth via telehealth, effectively operating as a distributed provider [1].

Market Trends Shaping DFW in 2026

Compounding under regulatory pressure. The FDA’s drug shortage designation for semaglutide is expected to be resolved in 2026, which would end the legal basis for compounding pharmacies to produce semaglutide copies. If this occurs, DFW clinics that exclusively prescribe compounded versions will need to pivot to branded Wegovy, tirzepatide, or other GLP-1 agents. Patients currently on compounded programs should ask their provider about their transition plan [7].

Employer wellness integration growing. Several large DFW employers have added GLP-1 medication coverage to their wellness benefit packages in 2025-2026, driven by actuarial analysis showing that GLP-1 treatment reduces downstream cardiovascular and diabetes care costs. This is accelerating insurance approvals in the Plano-Irving-Las Colinas corporate corridor and increasing the proportion of DFW patients accessing branded Wegovy through employer channels rather than cash-pay compounded programs [8].

Telehealth expansion into underserved DFW cities. Seven of the 14 cities in our coverage area — including Arlington (population 400,000+) and Irving (population 240,000+) — have no verified in-person semaglutide clinic. Telehealth providers, both national and DFW-based, are actively targeting these cities. As these markets develop, we expect in-person clinics to follow, particularly in Arlington and McKinney, which have the population density to support multiple providers [1][2].

Dallas-Fort Worth Semaglutide FAQ

How SemaVerified Works

SemaVerified is an independent research publication. We are not affiliated with any semaglutide clinic, pharmaceutical manufacturer, or insurance carrier. No clinic pays for placement in our database, rankings, or guides. Our revenue, if any, comes from display advertising and affiliate relationships with non-medical products only — never from the clinics we review [10].

Every clinic in our DFW database has been verified through a 5-step process: (1) Texas Medical Board license verification for the supervising physician; (2) Texas State Board of Pharmacy or FDA 503B registration check for the compounding pharmacy supplying the clinic; (3) direct outreach by phone or web inquiry to confirm current semaglutide availability and pricing; (4) review of published pricing pages, consultation fee disclosures, and monitoring protocols; and (5) a final transparency score based on how completely the clinic discloses all costs before the patient commits [1]. Clinics that declined to participate or could not confirm current pricing are excluded from our database entirely.

Our medical content is reviewed by Dr. Sarah Mitchell, PharmD, a licensed clinical pharmacist with experience in weight management pharmacotherapy. Dr. Mitchell reviews all clinical claims, drug interaction warnings, and dosing information for accuracy. She does not review or influence clinic rankings or pricing data, which is determined solely by our research team [10].

Editorial independence. Our editorial team has full control over which clinics are included, how they are ranked, and what is written about them. We do not accept payment to modify, remove, or improve a clinic’s standing in our database. If a clinic disputes our findings, we review the dispute and correct factual errors promptly — but we do not alter factual assessments in response to complaints without supporting evidence.

For full details on how we collect data, score clinics, and maintain independence, see our verification methodology and editorial policy.